At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 73 enrolled
Drug / intervention
CVL-354 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Double-blind (Investigator and Participant), First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CVL-354 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating CVL-354 and Placebo for Healthy Participants. Completed, enrolled 73 participants across 1 site.
Detailed Summary
This is a 2-part, double-blind, randomized, placebo-controlled, first-in-human trial evaluating a single ascending dose (4-way crossover, Part A) and multiple ascending doses (Part B) of CVL-354.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedDec 2021
Primary CompletionJan 2023
TodayJul 2026
First PostedDec 1, 2021
Enrollment StartOct 18, 2021
Primary CompletionJan 23, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.6 years ago
Interventions
CVL-354drug
Oral solution/suspension
Placebodrug
Placebo matched to CVL-354
CVL-354drug
Capsule